P-ECCO
11October2019

Fighting for growth in paediatric Inflammatory Bowel Disease

Amit Assa*/**, P-ECCO Member

Amit Assa 2019
Amit Assa
© ECCO

Growth retardation is commonly seen in children diagnosed with Inflammatory Bowel Disease (IBD), mainly those with Crohn's Disease (CD). The aetiology of poor growth in children with IBD is multifactorial and includes malnutrition, poor intake, increased nutritional needs, elevated inflammatory cytokines, genetic factors (parental height, CD susceptibility genes) and corticosteroid therapy. Growth retardation may be present years before diagnosis of IBD, and it commonly persists despite disease-specific treatments, with implications for final adult height and consequent social and psychological burden.

Posted in Volume 14, Issue 3, ECCO News, Committee News, P-ECCO

12June2019

Microbiome and diet are partners in CD pathogenesis and treatment

Johan Van Limbergen 2019
Johan Van Limbergen 
© ECCO
Konstantinos Gerasimidis wrc 2015
Konstantinos Gerasimidis
© ECCO

Johan Van Limbergen1,2, Konstantinos Gerasimidis3

Crohn’s Disease (CD) is increasing in incidence worldwide [1]. In spite of increased use of immune suppression, which has markedly changed the need for in-hospital care, paediatric CD remains associated with considerable morbidity as well as increased mortality [2, 3]. The onset of disease in childhood and adolescence often interferes with growth and development, both physically and psychologically. In a subset of patients, the progressive nature of disease may be associated with a fibrotic phenotype that does not respond adequately to the currently available immune suppressive medications, yet use of these medications is still associated with increased risk of myelosuppression, opportunistic infections, immune-mediated phenomena and malignancy [2, 4–6]. 

Posted in ECCO News, Volume 14, Issue 2, Committee News, P-ECCO

30April2019

New Committee Members in P-ECCO

David Wilson, P-ECCO Chair

David WilsonDavid Wilson
© ECCO

The mission of the Paediatric Committee of ECCO is improving knowledge on paediatric-specific IBD issues as well as supporting and facilitating research into paediatric IBD. During the ECCO Congress in Copenhagen, P-ECCO said goodbye to Patrick van Rheenen and Jaroslaw Kierkus. We greatly thanked them for all their contributions to P-ECCO and welcomed two new members: Johan van Limbergen and Amit Assa

Posted in ECCO News, ECCO'19, Committee News, Volume 14, Issue 1, Congress News, P-ECCO

08June2018

Challenges in using new drugs in children

Lissy de Ridder, P-ECCO Member

Lissy de Ridder
Lissy de Ridder
© ECCO

Paediatric Inflammatory Bowel Disease (IBD) accounts for 10%15% of all incident cases of IBD, while the incidence in children under 10 years old is rising most rapidly [1, 2]. Children and adolescents present with a more severe phenotype of disease and have both higher and unique risks (e.g. fistulising disease, growth failure, pubertal delay) and a longer disease duration, given that IBD is a lifelong disease. 

Posted in ECCO News, Committee News, Volume 13, Issue 2, P-ECCO

27April2018

4th International Symposium on Paediatric Inflammatory Bowel Disease - PIBD 2017

David Wilson, P-ECCO Member

David Wilson
David Wilson © ECCO

The first International Symposium on Paediatric Inflammatory Bowel Disease (PIBD) took place in Rome in 2006 and was hosted by Salvatore Cucchiara. It was followed by the second PIBD Symposium in 2009 in Paris, hosted by Frank Ruemmele. Both were private initiatives. After a pause while plans to alternate PIBD Symposia between venues in Europe and North America were considered, the paediatric IBD Porto group of ESPGHAN took over all organisation. This resulted in the 3rd Symposium in Rotterdam in 2014, hosted by Hankje Escher.

Posted in ECCO News, Committee News, Volume 13, Issue 1, P-ECCO

27April2018

Paediatric news from the 13th Congress of ECCO 2018

Jaroslaw Kierkus, P-ECCO Member

Jaroslaw Kierkus
Jaroslaw Kierkus
© ECCO

The 13th Congress of ECCO is behind us: So many thoughts, and important new targets for research into therapy, diagnosis and management. Everything in one place, in wonderful Vienna.

From the point of view of the paediatrician, the Congress offered insights into numerous new predictive tools. It is not surprising that research is heading in this direction, for ultimately “to know” is halfway towards “to treat”. Looking more closely at this topic: What can we predict and by what means can we predict it?

Posted in ECCO'18, ECCO News, Committee News, Congress News, Volume 13, Issue 1, P-ECCO

12December2017

The newly revised ECCO/ESPGHAN Paediatric UC Guideline

Richard Russell, P-ECCO Member

Richard RussellRichard Russell  ©  ECCO

The revision of the Paediatric UC Guideline for children has been carried out jointly by the ESPGHAN Porto IBD group and ECCO. This revised guideline has updated the previous separate guidelines on Acute Severe UC and Ambulatory UC [1,2] and combined them into one document. The guideline was developed on the basis of an intensive literature search and careful evidence grading; the Oxford levels of evidence were used for the latter purpose after it became clear that the guideline was being developed too soon for the use of GRADE methodology. A summary of all the evidence assimilated during the guideline development will be published as supplementary tables so that others can benefit from the intensive search without having to redo the work.

Posted in ECCO News, Committee News, P-ECCO, Volume 12, Issue 4